Compare AMETEK, Inc. (AME) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Becton Dickinson and Co — how do they compare? AMETEK, Inc. trades at $257.42 (market cap $58.76B), while Becton Dickinson and Co trades at $179 (market cap $49.41B). The key difference: AMETEK, Inc. is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| AME | BDX | |
|---|---|---|
Market Cap | $58.76B | $49.41B |
Sector | Industrials | Health |
52-Week High | $256.30 | $185.39 |
52-Week Low | $179.28 | $138.62 |
Enterprise Value | $60.30B | $65.51B |
Dividend Yield | 0.53% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.
Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
